Fibrocell Science Inc (FCSC) Rating Lowered to Sell at Zacks Investment Research

Zacks Investment Research downgraded shares of Fibrocell Science Inc (NASDAQ:FCSC) from a hold rating to a sell rating in a research note issued to investors on Monday.

According to Zacks, “Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell’s most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company’s lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma. “

Several other brokerages also recently issued reports on FCSC. ValuEngine upgraded Fibrocell Science from a sell rating to a hold rating in a report on Thursday, July 20th. HC Wainwright set a $6.00 price target on Fibrocell Science and gave the company a buy rating in a report on Wednesday, August 9th.

Fibrocell Science (FCSC) opened at 2.50 on Monday. The stock’s market capitalization is $36.79 million. The company has a 50-day moving average price of $3.47 and a 200-day moving average price of $2.29. Fibrocell Science has a 12-month low of $1.57 and a 12-month high of $4.64.

Fibrocell Science (NASDAQ:FCSC) last announced its quarterly earnings results on Wednesday, August 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.31). Fibrocell Science had a negative return on equity of 293.07% and a negative net margin of 4,307.60%. On average, equities research analysts forecast that Fibrocell Science will post ($2.30) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Fibrocell Science Inc (FCSC) Rating Lowered to Sell at Zacks Investment Research” was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.com-unik.info/2017/08/18/fibrocell-science-inc-fcsc-rating-lowered-to-sell-at-zacks-investment-research.html.

A number of hedge funds have recently made changes to their positions in the stock. Parametric Portfolio Associates LLC increased its stake in shares of Fibrocell Science by 264.0% in the second quarter. Parametric Portfolio Associates LLC now owns 48,259 shares of the company’s stock valued at $194,000 after buying an additional 35,000 shares in the last quarter. Creative Planning increased its stake in shares of Fibrocell Science by 395.3% in the second quarter. Creative Planning now owns 61,090 shares of the company’s stock valued at $245,000 after buying an additional 48,755 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in shares of Fibrocell Science by 272.4% in the fourth quarter. Renaissance Technologies LLC now owns 194,000 shares of the company’s stock valued at $122,000 after buying an additional 141,900 shares in the last quarter. Hedge funds and other institutional investors own 55.31% of the company’s stock.

Fibrocell Science Company Profile

Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.

Get a free copy of the Zacks research report on Fibrocell Science (FCSC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

What are top analysts saying about Fibrocell Science Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Fibrocell Science Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit